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I. INTRODUCTION 
Professor Allen’s analysis in Dense Women is timely and insightful.1 
Briefly, her argument is this: dense breast tissue renders mammograms more 
difficult to read.2 Hence, those mammograms are less likely to detect cancer.3 
While women with this condition may be better able to make informed 
decisions if they are told their tissue is dense, the information should come not 
from legal mandates, but rather from public information campaigns and 
similar voluntary outreach.4 State-prescribed disclosures, as Allen proposes, 
do not just interfere with women’s autonomy; they also pose potential legal 
perils for physicians.5 The threat of malpractice litigation for failure to address 
density can not only distort physician-patient communication, but can 
inappropriately ramp up screening standards by legislative fiat rather than by 
sound medical judgment.6 
This Response proposes that Allen’s analysis goes astray in one respect—
namely, her argument that notification statutes undermine women’s 
autonomy.7 Elsewhere, however, she hits the mark squarely, particularly her 
conclusion that excessive concerns about density can promote increased levels 
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 1 See generally Alena Allen, Dense Women, 76 OHIO ST. L.J. 847 (2015).  
 2 Id. at 883. 
 3 Id. at 861.  
 4 Id. at 894–97. 
 5 Id. at 873–88. 
 6 Id. at 891–94. 
 7 Allen, supra note 1, at 873–78. 
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of screening that can, in turn, do more harm than good.8 Indeed, there are 
additional considerations supporting that conclusion, which this commentary 
will explore. 
II. THE AUTONOMY ARGUMENT 
Allen distinguishes among statutes according to their level of 
directiveness.9 After telling the woman that her breast tissue is dense, highly 
directive language would say, for example: “This information about the result 
of your mammogram is given to you to raise your awareness. Use this 
information to talk to your doctor about your own risks for breast cancer. At 
that time, ask your doctor if more screening tests might be useful, based on 
your risk.”10 Moderately directive language, by comparison, would say: “This 
information is being provided to raise your awareness and to encourage you to 
discuss with your health care providers your dense breast tissue and other 
breast cancer risk factors. Together, you and your physician can decide if 
additional screening options are right for you.”11 
Such instructions, Allen maintains, “dictate to women how they should 
use the information given” to them.12 The instructions “command,”13 “unduly 
trampl[e] upon,”14 and “direct[] women towards the preferred choice,”15 with 
the net effect being that “the ability of women to make an autonomous choice 
is now being thwarted by the state.”16 Moreover, this information is delivered 
right after the mammogram, the time in which the woman’s “ability to process 
the information is compromised by worry and anxiety.”17 In the end, says 
Allen, the directive statutes “usurp the power of women to make independent 
unbiased choices about their medical care.”18 
Dictate. Command. Trample. Direct. Thwart. Usurp. Let us take another 
look. The most highly directive language simply tells women to have a 
conversation: “Use this information to talk to your doctor . . . . [and] ask your 
doctor if more screening tests might be useful . . . .”19 This language does not 
tell women how the conversation should go or what the woman and doctor 
should conclude, nor does it direct women to get additional screening. It just 
                                                                                                                 
 8 Id. at 879. 
 9 Id. at 873–78. 
 10 Id. at 874 (quoting ALA. CODE § 22-13-71(a) (Lexis Nexis Supp. 2014)). 
 11 Id. at 875–76 (quoting ARIZ. REV. STAT. ANN. § 36-415(A) (Supp. 2014)). 
 12 Id. at 875. 
 13 Allen, supra note 1, at 875. 
 14 Id. at 878. 
 15 Id. at 897–98. 
 16 Id. at 897. 
 17 Id. at 896. 
 18 Id. at 873. 
 19 Allen, supra note 1, at 874 (quoting ALA. CODE § 22-13-71(a) (Lexis Nexis Supp. 
2014)).  
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says: “talk to your doctor.”20 Nevertheless, Allen determines that this 
statement on a piece of paper will “usurp the power of women.”21  
Allen’s leap is more than a non sequitur that could be deemed fairly 
insulting to women.22 More importantly, evidence indicates that Allen’s view 
here is empirically incorrect. First, there is the commonplace reality that many 
people often disregard health warnings, including prescriptions from their own 
doctors. Many of us continue to smoke, eat unhealthy foods, abjure exercise, 
consume alcohol beyond moderation, and fail to take our hypertension 
medications faithfully.  
More to the point, a recent meta-analysis expressly focused on studies of 
women with dense breasts.23 In one of the studies analyzed, women were 
randomly assigned either to a control group that did not receive notification 
about breast density along with their mammography results, or to an 
intervention group that did receive this information.24 Contrary to Allen’s 
proposal that, at the conclusion of a mammography screening a woman’s 
“ability to process the information is compromised by worry and anxiety,”25 
this study found that: 
At [four] weeks, more women in the intervention group had 
statistically significantly increased knowledge of breast 
density . . . and were more likely to perceive themselves as having 
elevated breast cancer risk. These differences did not persist at [six] 
months. Psychological distress, breast cancer worry, and 
preoccupation with breast cancer did not differ between groups.26 
Certainly anxiety is increased when the woman’s mammography result is 
positive.27 Being told that one may actually have cancer is indeed cause for 
                                                                                                                 
 20 Id.  
 21 Id. at 873. Common definitions of “usurp” include “to seize,” take without lawful 
right, commandeer, appropriate, grab, arrogate, and take over. See Usurp, 
DICTIONARY.COM, http://www.dictionary.com/browse/usurp [https://perma.cc/BPM3-N45Z]; 
Usurp, MERRIAM-WEBSTER.COM, http://www.merriam-webster.com/dictionary/usurp 
[https://perma.cc/95H2-YZPT].  
 22 On what basis, one wonders, can one conclude that a directive to “talk to your 
doctor” supposedly renders an ordinarily competent woman too helpless to make her own 
decisions? See Allen, supra note 1, at 874 (quoting ALA. CODE § 22-13-71(a)).  
 23 See generally Joy Melnikow et al., Supplemental Screening for Breast Cancer in 
Women with Dense Breasts: A Systematic Review for the U.S. Preventive Services Task 
Force, 164 ANNALS INTERNAL MED. 268 (2016). 
 24 Id. at 274 (citing Joan L. Bottorff et al., Women’s Responses to Information on 
Mammographic Breast Density, 39 CAN. J. NURSING RES. 42–43 (2007)).  
 25 Allen, supra note 1, at 896. 
 26 Melnikow et al., supra note 23, at 274.   
 27 Albert L. Siu, U.S. Preventive Servs. Task Force, Screening for Breast Cancer: 
U.S. Preventive Services Task Force Recommendation Statement, 164 ANNALS INTERNAL 
MED. 279, 290 (2016).  
76 A RESPONSE TO ALENA ALLEN [2016 
concern. This, however, is not the same as being told one has dense breast 
tissue. As noted, there is no evidence that such information, by itself, causes 
psychological distress.28 Conversely, evidence suggests that the information 
increases women’s knowledge about breast cancer, although the enhanced 
understanding did not persist for even six months.29 
III. THE LIKELIHOOD AND PROBLEMS OF RAMPED-UP SCREENING 
Allen suggests that the notification statutes are likely to lead to increased 
screening for women with dense breasts and that such a ramp-up is not 
necessarily a good thing.30 While Allen does get this right, I would like to re-
frame the discussion.  
A. Likelihood of Ramped-up Screening 
A legal requirement that a radiologist tell a woman that she has dense 
breast tissue does not inherently mean that the doctor must change the way he 
or she treats patients. Arguably, the only necessary change is that the doctor 
(or his or her office staff) must hand the requisite paperwork to the woman or 
include the required wording in an electronic message. If failure to provide 
this information is a potential source of liability, the fix is simple enough.31 
Nevertheless, as a broad reality, it takes very little to prompt physicians to 
fear malpractice liability and to modify their practices far more than the actual 
liability risk might suggest. As a long-time medical school professor, I have 
often emphasized to my students and residents that doctors often learn about 
law the same way teenagers learn about sex: they ask each other, and the 
mythology they generate is comparable. More eloquently, Alex Capron has 
said, “If patients behaved as irrationally about treatments as physicians do 
about liability, the patients would be labeled incompetent.”32 In other words, 
physicians generally need very little prompting to become concerned about a 
hypothetical malpractice risk and to modify their practices in ways more 
commensurate with the depth of their fears than with the magnitude of the risk. 
That said, important complexities should be noted. First, in the case of 
mammography and follow-up conversations, two different physicians are 
usually involved, not just one. The physician with the legal obligation to notify 
the woman is ordinarily the radiologist, since he or she is often the one to 
make that diagnosis. However, a new duty to pass along information is not the 
                                                                                                                 
 28 See Bottorff et al., supra note 24, at 38. 
 29 Id. 
 30 Allen, supra note 1, at 879–80.  
 31 Id. at 884 (explaining that density notification statutes in most states broaden 
malpractice risk by creating a standard of care, which, if not followed, may lead to medical 
malpractice liability). 
 32 Alexander Morgan Capron, Legal and Ethical Problems in Decisions for Death, 14 
L. MED. & HEALTH CARE 141, 142 (1986). 
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radiologist’s greatest concern. Rather, potential liability for failing to diagnose 
density in the first place will cause the greater worry.33 If that leads to 
diagnosing more women as dense, then concerns about excessive follow-up 
screenings are amplified.34 
Typically, the conversation that follows notification is between the woman 
with dense tissue and her primary care physician (PCP), not the radiologist. 
Here, the pressure to recommend additional screening could depend, in part, 
on precisely how the woman received her mammography results and 
notification. Where a result is positive, the radiologist has a strong duty to alert 
the PCP, so the PCP can then respond to the patient. Conversely, benign 
results of routine screenings do not necessarily prompt any alerts to PCPs. 
They may not become aware of mammography results or the density 
determination until they browse the report during the patient’s next visit, 
whenever that may be, or if the woman makes an appointment after reading 
the message about density. 
A PCP who had no duty to diagnose breast density and no statutory duty 
to alert the patient may not feel any special urgency to propose additional 
screening. If that PCP is keeping abreast of the relevant literature, then the 
conversation may not result in further screening. The most up-to-date studies 
suggest that although additional screening can indeed identify a few more 
cases of breast cancer, the price is not just increased anxiety and distress—it 
can include radiation-induced breast cancer.35 On the other hand, many PCPs 
may indeed feel pressure to recommend additional screening where a patient 
shares the notification about her dense breasts and asks about follow-up 
testing. The course of least resistance (and which would take the least time out 
of a busy PCP’s schedule) may well be to say, “Sure, let’s schedule some 
tests.” 
Allen suggests that an aggressive public information campaign about 
breast density and its potential implications would be superior to notification 
                                                                                                                 
 33 Diagnosing breast density is not a simple matter. As Allen notes, there are four 
categories of density: (a) almost entirely fatty, (b) scattered areas of figro-glandular 
density, (c) heterogeneous mixture of dense and fatty tissue, and (d) extremely dense 
tissue. Categories (c) and (d) generally qualify for deeming a woman to have dense breasts. 
Allen, supra note 1, at 862 (citing AM. COLL. OF RADIOLOGY, ACR BI-RADS ATLAS—
MAMMOGRAPHY 124 (5th ed. 2013), http://www.acr.org/~/media/ACR/Documents/ 
PDF/QualitySafety/Resources/BIRADS/01%20Mammography/02%20%20BIRADS%20Mam
mography%20Reporting.pdf [https://perma.cc/WN3N-GJTZ]). Diagnoses of density can vary 
not only from one radiologist to another, but for the same radiologist from one time to the 
next, for the same patient. See, e.g., Melnikow et al., supra note 23, at 271. 
 34 Indeed, “[t]he likelihood of a woman being told she has dense breasts varies 
substantially according to which radiologist interprets her mammogram.” Brian L. Sprague 
et al., Variation in Mammographic Breast Density Assessments Among Radiologists in 
Clinical Practice, 165 ANNALS INTERNAL MED. 1, 1 (July 19, 2016), 
http://annals.org/article.aspx?articleid=2534407 [https://perma.cc/99EQ-V9GE].  
 35 See Siu, supra note 27, at 290. 
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statutes.36 Maybe so, maybe not. Widespread public discussion, public service 
announcements in the media, news stories, and the like can have their own 
effect on a physician’s psyche and, in the end, could be just as likely to 
pressure physicians into excessive screening as notification statutes. Whatever 
the source of patients’ questions and requests, whether a statutorily-required 
piece of paper or a heavy media campaign, physicians can be persuaded into 
ramping up screening practices. Hence, Allen’s proposals for reducing 
pressures on physicians may not work as hoped. 
B. Problems of Ramped-up Screening 
Allen rightfully argues that there is a great need for diligence and 
circumspection when screening is ramped up solely on the ground that a 
woman’s breast tissue is dense.37 The U.S. Preventive Services Task Force 
(USPSTF) recently reasserted the guidelines initially issued in 2009, 
recommending biennial, not annual, mammography for average-risk women 
beginning at age fifty, with individualized discussions and decisions for 
women under that age.38 While recognizing that more frequent screening can 
detect a few more cases of cancer, the USPSTF emphasizes that the harms of 
excessive screening are very real: 
The most important harm is the diagnosis and treatment of 
noninvasive and invasive breast cancer that would otherwise not have 
become a threat to a woman’s health, or even apparent, during her 
lifetime (that is, overdiagnosis and overtreatment). False-positive 
results are common and lead to unnecessary and sometimes invasive 
follow-up testing, with the potential for psychological harms (such as 
anxiety). False-negative results (that is, missed cancer) also occur and 
may provide false reassurance. Radiation-induced breast cancer and 
resulting death can also occur, although the number of both of these 
events is predicted to be low.39 
The USPSTF’s observation regarding the likelihood of false-positive 
results merits amplification. We begin by explaining the concepts of 
sensitivity, specificity, and positive predictive value. The sensitivity of a 
screen or diagnostic test is the likelihood that, if the disease or condition is 
present in the patient, the test will detect it (i.e., if someone has the disease, 
how often will the test be positive). Specificity refers to the likelihood that a 
positive result actually reflects the presence of the condition/disease, rather 
than something else (i.e., if the person does not have the disease, how often 
                                                                                                                 
 36 Allen, supra note 1, at 896. 
 37 See id. at 900. 
 38 See Siu, supra note 27, at 279. 
 39 Id. at 280. 
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will the test be negative).40 Positive predictive value (PPV), in turn, “answers 
the question: ‘How likely is it that this patient has the disease given that the 
test result is positive?’”41 
Consider the following example. For illustrative simplicity, let us consider 
1,000 women and say, hypothetically, that eight of these 1,000 women 
actually have breast cancer. Suppose further that the sensitivity of 
mammography is 90%—that for every ten patients who actually have breast 
cancer, the test picks up nine of them. Suppose further that the test’s 
specificity is 93%—that is, for patients who do not have the disease, the test 
will incorrectly say that 7% of them do have it, even while properly yielding 
negative results for the other 93% who do not have the disease.  
We can now trace out some implications. Per our earlier hypothetical 
numbers, of the 1,000 women, eight have the disease. Therefore, 992 do not. 
We have assumed, hypothetically, that the sensitivity for this test is 90% and 
the specificity is 93%. Therefore, with a sensitivity of 90%, the test will 
correctly pick up seven out of the eight women who actually have the disease, 
but will miss that last affected woman. In addition, the test will look at the 992 
women who do not have the disease. With a specificity of 93%, the test will 
correctly say that 93% of those disease-free women do not have the disease 
and will incorrectly tell us that 7% of them do have it. Thus, seventy of those 
992 disease-free women will be falsely diagnosed as positive.  
Overall, the test will show seventy-seven positive results: seven will be 
true-positives and seventy will be false-positives. As a result, the PPV is only 
10%. For every ten women who are said by this test to have the disease, only 
one will actually have the disease. 
Let us now turn to actual figures for sensitivity, specificity, and PPV for 
women who receive supplemental screening because they have dense breast 
tissue. As Allen discussed, sensitivity and specificity of mammography for 
women with dense breast tissue is significantly lower than that for less dense 
women.42 Thus, we want to consider sensitivity, specificity, and PPV for 
various kinds of follow-up screening that might be undertaken for women who 
have been identified as having dense tissue.  
Consider ultrasound results for these women with a negative mammogram 
but dense tissue. Here, sensitivity ranges from 80% to 83%, specificity from 
86% to 94%, and PPV from 3% to 8%.43 That is, for every 100 women whose 
ultrasound concludes “this woman has cancer,” only three to eight of those 
women will actually have cancer.44  
The numbers for magnetic resonance imaging (MRI) are analogous. 
Sensitivity ranges from 75% to 100%, specificity from 78% to 94%, and, at 
                                                                                                                 
 40 Abdul Ghaaliq Lalkhen & Anthony McCluskey, Clinical Tests: Sensitivity and 
Specificity, 8 CONTINUING EDUC. ANESTHESIA CRITICAL CARE & PAIN 221, 221 (2008). 
 41 Id. at 221–22. 
 42 See Allen, supra note 1, at 861; see also Siu, supra note 27, at 285. 
 43 Melnikow et al., supra note 23, at 268. 
 44 See id.  
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best, PPV ranges from 3% to 33% across three studies.45 Thus, for every 100 
women whose MRI says they do have breast cancer, maybe only three women 
actually have it—or maybe as many as thirty-three, or somewhere in 
between.46 
Perhaps it is for these reasons that there are no accepted clinical practice 
guidelines to direct adjunctive screening for a woman with dense breast tissue 
whose mammogram is negative.47 The caution is warranted: early detection 
does not necessarily save lives. For some kinds of cancer it does, and for 
others, not really.  
Screening has been shown to be helpful for some kinds of cancer, such as 
colon and cervical cancer.48 For other kinds of cancer, screening has not been 
shown to reduce mortality rates.49 A Cochrane review of several controlled 
clinical trials, with nearly 350,000 participants, found that prostate screening 
did not significantly reduce the death rate from prostate cancer.50 Similarly, a 
twenty-five year longitudinal study in Canada, with nearly 90,000 women 
from 40–59 years of age, found that annual mammograms did not reduce 
breast cancer mortality.51  
The unfortunate reality is that “some tumors will lead to death irrespective 
of when they are detected and treated. Meanwhile, aggressive early screening 
has a slew of negative health effects. Many cancers grow slowly and will do 
no harm if left alone, so people end up having unnecessary thyroidectomies, 
mastectomies and[,] prostatectomies.”52 Perhaps the greatest challenge in the 
                                                                                                                 
 45 Id. 
 46 See id. 
 47 See Siu, supra note 27, at 286. 
 48 Megan Scudellari, Myths that Will Not Die, 528 NATURE 322, 323 (2015). 
 49 See generally Nazmus Saquib et al., Does Screening for Disease Save Lives in 
Asymptomatic Adults? Systematic Review of Meta-Analyses and Randomized Trials, 44 
INT’L J. EPIDEMIOLOGY 264 (2015) (finding that few screening tests for nineteen major 
disease conditions reduce mortality). 
 50 Dragan Ilic et al., Screening for Prostate Cancer (Review), COCHRANE DATABASE 
OF SYSTEMATIC REVS. 2–3 (2013), http://onlinelibrary.wiley.com/doi/10.1002/14651858 
.CD004720.pub3/epdf [https://perma.cc/EL8H-HJQD]. More recently, a ten-year study of 
1,643 men with prostate cancer concluded that the death rate did not differ significantly 
between men who were treated with surgery and radiation versus those who declined such 
treatment. See generally J.L. Donovan et al., Patient-Reported Outcomes After Monitoring, 
Surgery, or Radiotherapy for Prostate Cancer, NEW ENG. J. MED. (Sept. 14, 2016), 
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1606221 [https://perma.cc/8GS6-QV8U]. 
 51 See generally Anthony B. Miller et al., Twenty Five Year Follow-up for Breast 
Cancer Incidence and Mortality of the Canadian National Breast Screening Study: 
Randomised Screening Trial, 348 Brit. Med. J. g366 (2014), 
http://www.bmj.com/content/bmj/348/bmj.g366.full.pdf [https://perma.cc/FX6E-VEV5].  
 52 Scudellari, supra note 48, at 323. In southwest Korea, an aggressive program for 
early detection of thyroid cancer has led to a great increase in the numbers of thyroid 
cancers detected. Id. at 322. Many people diagnosed have had their thyroid glands removed 
and been placed on lifelong drug regimen, with notable risks for both. Id. Nevertheless, 
there has been no change whatever in the death rate from thyroid cancer in that region. Id. 
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realm of breast cancer science, diagnosis, and treatment may be to figure out 
how to distinguish better between fast- and slow-growing tumors. 
In the end we can conclude that, on the whole, Allen is mostly right. The 
problem is not that a piece of paper telling women to talk to their doctors will 
somehow render women less competent to engage in a conversation or to 
make their own decisions. Rather, the problem is that the science does not 
support the politics. Mandatory disclosures regarding density of breast tissue 
appear to have a fairly high likelihood of prompting increased screening for 
this large group of women, in the absence of solid evidence that the 
information will actually make a significant, population-wide difference in 
morbidity or mortality from breast cancer.53 Although some women will be 
diagnosed earlier through such extra screens, perhaps with benefit to them, the 
poor PPV of these tests suggests that far more women will undergo needless 
interventions, and in some cases harm-causing treatments, for no good reason. 
As the new USPSTF recommendations recognize: 
Increased breast density is common in the general population; 
however, critical questions remain about how best to manage this 
condition and to support these women. Research to help improve the 
validity and reproducibility of serial BIRADS assessments would be 
useful if breast density is to be considered as a factor for personalized, 
risk-based approaches to breast cancer screening.54 
                                                                                                                 
 53 See supra Part.III.B.  
 54 Siu, supra note 27, at 287. 
